



Collaborative Working Project Executive Summary

Project title	Review of the current Chemotherapy service pathway and provision for Systemic anti-cancer therapies (SACT) across Lancashire and South Cumbria Cancer Alliance
Partner organisation/s	Lancashire Teaching Hospitals NHS Trust Sanofi
Project rationale	<p>Across the Lancashire and South Cumbria area, pressures from an increasing incidence of Cancer, case complexity, increasing referrals into the specialist service and a vast geographical area may be having a significant impact on the management of Cancer patients across the area.</p> <p>The treatment and the experience of the patient is at the forefront of the specialist team and they have identified that the Chemotherapy service that deals with SACT therapies may need to change, in order, to meet these increasing demands and ensure that their patients receive the best possible care and have a great experience of the service.</p> <p>Therefore, in the first instance, it is important that the specialist team fully understand how patients move through the SACT pathway from each area within the Lancashire and South Cumbria region and identify where potential pressure points may be, within the pathway, which could result in the patient spending an inappropriate amount of time in hospital, not being seen or treated within a timely manner, not being treated at a more suitable location, or not having a good experience of the service.</p> <p>Our plan is to carry out a clear and effective review of the current service provision and referral pathway to understand the current challenges and 'bottle necks' that may exist within the Lancashire and South Cumbria SACT service and pathway. This will help us to develop an options appraisal which, through engagement with our regional trust partners, will allow us to establish and implement a service provision and pathway that will be future proofed for now and the future. In order to do this, project management support has been requested from Sanofi to work alongside dedicated NHS staff to help us deliver on this piece of work in a timely manner as well as the roll</p>

	<p>out any changes to the service and pathway provision across the Lancashire and South Cumbria area.</p>
<p>Project period</p>	<p>Q4 2021 to Q2 2022</p>
<p>Project objectives</p>	<p><i>There are several key benefits that we believe that this piece of work will deliver</i></p> <p>Patients:</p> <ul style="list-style-type: none"> • <i>Patients might expect more equitable and consistent care as well as improved and quicker access to care,</i> • <i>Patients can expect to spend less time in hospital</i> • <i>Patients will have better access to treatment options with the appropriate treatments being made more convenient for patients</i> • <i>Better experience of the system and overall, better patient experience.</i> • <i>We would expect patients to be treated at the most appropriate centre that is closest to their place of residence</i> <p>Lancashire Hospital Trusts / local CCGs:</p> <ul style="list-style-type: none"> • <i>Better and more efficient patient pathway for SACT administration across the Lancashire area</i> • <i>Reduced wait times and increased capacity within the Chemotherapy pathway</i> • <i>Potentially, increased number of patients assessed and potentially treated in a more timely manner</i> • <i>Better understanding and knowledge of SACT treatment among local HCPs</i> • <i>Ensure processes in Chemotherapy therapy are standardised and safe</i> • <i>Increased engagements with appropriate patients to provide additional support and education</i> <p>Sanofi:</p> <ul style="list-style-type: none"> • <i>A better understanding of the Chemotherapy service and pathway across the Lancashire area</i> • <i>Greater understanding of the needs of the customer in Chemotherapy</i> • <i>Improved reputation with relevant NHS organisations across the Lancashire area</i>

	<ul style="list-style-type: none"> • <i>As Sanofi produce medicines in this area, if overall patient care is optimised there may be an increase in the usage of these</i> <p><i>We will assess the effectiveness and impact of this project through the measurement of the following;</i></p> <ul style="list-style-type: none"> • <i>Distance and travel time for patients to be seen and treated by a specialist</i> • <i>Where patients are being seen and treated in terms of NHS organisation</i> • The time which a patient is spending in the pathway compared to the baseline • The time patients are spending in hospital, in order to receive treatment • Wait time for patients to be prescribed and initiated on SACT therapy. • How and where patients are receiving treatment in relation to where they live. • Patient satisfaction based on their service experience
<p>Contact details</p>	<p><u>Sanofi Aventis</u></p> <p>Fleur Chandler</p> <p>Head of Market Access UK&IE</p> <p>Sanofi Aventis</p> <p>410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT.</p> <p>GB-patientaccess@sanofi.com</p> <p><u>NHS</u></p> <p>Dr Ruth Board</p> <p>Consultant Medical Oncologist and SACT Lead,</p> <p>Lancashire Teaching Hospitals</p> <p>Rosemere Cancer Centre</p> <p>Royal Preston Hospital</p> <p>Sharoe Green Lane</p>



Lancashire Teaching Hospitals
NHS FoundationTrust

Preston PR2 9HT

Ruth.Board@lthtr.nhs.net